These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 33952632)

  • 21. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling.
    Rodrigues-Diez R; González-Guerrero C; Ocaña-Salceda C; Rodrigues-Diez RR; Egido J; Ortiz A; Ruiz-Ortega M; Ramos AM
    Sci Rep; 2016 Jun; 6():27915. PubMed ID: 27295076
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping the structural brain changes in Alzheimer's disease: the independent contribution of two imaging modalities.
    Canu E; McLaren DG; Fitzgerald ME; Bendlin BB; Zoccatelli G; Alessandrini F; Pizzini FB; Ricciardi GK; Beltramello A; Johnson SC; Frisoni GB
    J Alzheimers Dis; 2011; 26 Suppl 3(Suppl 3):263-74. PubMed ID: 21971466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FK506 attenuates intracerebroventricular streptozotocin-induced neurotoxicity in rats.
    Arora RB; Kumar K; Deshmukh RR
    Behav Pharmacol; 2013 Oct; 24(7):580-9. PubMed ID: 26057771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer-induced AMPA glutamate receptor signaling deficits.
    Miller EC; Teravskis PJ; Dummer BW; Zhao X; Huganir RL; Liao D
    Eur J Neurosci; 2014 Apr; 39(7):1214-24. PubMed ID: 24713000
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An MRI brain atrophy and lesion index to assess the progression of structural changes in Alzheimer's disease, mild cognitive impairment, and normal aging: a follow-up study.
    Zhang N; Song X; Zhang Y; Chen W; D'Arcy RC; Darvesh S; Fisk JD; Rockwood K;
    J Alzheimers Dis; 2011; 26 Suppl 3():359-67. PubMed ID: 21971475
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcineurin is involved in retrieval of passive avoidance memory and synaptic plasticity impairment induced by Nandrolone administration in adolescent male rats.
    Moradpour F; Moazedi AA; Pourmotabbed A; Zarei F
    Neurobiol Learn Mem; 2019 Sep; 163():107032. PubMed ID: 31173920
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-modal MRI investigation of volumetric and microstructural changes in the hippocampus and its subfields in mild cognitive impairment, Alzheimer's disease, and dementia with Lewy bodies.
    Mak E; Gabel S; Su L; Williams GB; Arnold R; Passamonti L; Vazquez Rodríguez P; Surendranathan A; Bevan-Jones WR; Rowe JB; O'Brien JT
    Int Psychogeriatr; 2017 Apr; 29(4):545-555. PubMed ID: 28088928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway.
    Yu JJ; Zhang Y; Wang Y; Wen ZY; Liu XH; Qin J; Yang JL
    Psychopharmacology (Berl); 2013 Jan; 225(2):361-72. PubMed ID: 22875481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis.
    Breuer K; Werfel T; Kapp A
    Am J Clin Dermatol; 2005; 6(2):65-77. PubMed ID: 15799678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropathological basis of magnetic resonance images in aging and dementia.
    Jagust WJ; Zheng L; Harvey DJ; Mack WJ; Vinters HV; Weiner MW; Ellis WG; Zarow C; Mungas D; Reed BR; Kramer JH; Schuff N; DeCarli C; Chui HC
    Ann Neurol; 2008 Jan; 63(1):72-80. PubMed ID: 18157909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Position statement: topical calcineurin inhibitors in atopic dermatitis.
    Remitz A; De Pità O; Mota A; Serra-Baldrich E; Vakirlis E; Kapp A
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2074-2082. PubMed ID: 30288799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcineurin inhibitors regulate fibroblast growth factor 23 (FGF23) synthesis.
    Bär L; Großmann C; Gekle M; Föller M
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Nov; 390(11):1117-1123. PubMed ID: 28761977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacodynamic analysis of tacrolimus and cyclosporine in living-donor liver transplant patients.
    Fukudo M; Yano I; Masuda S; Fukatsu S; Katsura T; Ogura Y; Oike F; Takada Y; Tanaka K; Inui K
    Clin Pharmacol Ther; 2005 Aug; 78(2):168-81. PubMed ID: 16084851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hippocampal 'zipper' slice studies reveal a necessary role for calcineurin in the increased activity of L-type Ca(2+) channels with aging.
    Norris CM; Blalock EM; Chen KC; Porter NM; Thibault O; Kraner SD; Landfield PW
    Neurobiol Aging; 2010 Feb; 31(2):328-38. PubMed ID: 18471936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of calcineurin/NFAT in SFRP2 induced angiogenesis--a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus.
    Siamakpour-Reihani S; Caster J; Bandhu Nepal D; Courtwright A; Hilliard E; Usary J; Ketelsen D; Darr D; Shen XJ; Patterson C; Klauber-Demore N
    PLoS One; 2011; 6(6):e20412. PubMed ID: 21673995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Calcineurin inhibitors in renal transplantation: what is the best option?
    Tanabe K
    Drugs; 2003; 63(15):1535-48. PubMed ID: 12887261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcineurin inhibition with systemic FK506 treatment increases dendritic branching and dendritic spine density in healthy adult mouse brain.
    Spires-Jones TL; Kay K; Matsouka R; Rozkalne A; Betensky RA; Hyman BT
    Neurosci Lett; 2011 Jan; 487(3):260-3. PubMed ID: 20970476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tacrolimus for the prevention and treatment of rejection of solid organ transplants.
    Scalea JR; Levi ST; Ally W; Brayman KL
    Expert Rev Clin Immunol; 2016; 12(3):333-42. PubMed ID: 26588770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel use of FDA-approved drugs identified by cluster analysis of behavioral profiles.
    Tucker Edmister S; Del Rosario Hernández T; Ibrahim R; Brown CA; Gore SV; Kakodkar R; Kreiling JA; Creton R
    Sci Rep; 2022 Apr; 12(1):6120. PubMed ID: 35449173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.